



**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW

Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbalà
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messinger
Judith U. Kim
Jeffrey T. Helvey
Eldora L. Ellison
Donald R. Banowitz

Peter A. Jackman
Brian J. Del Buono
Mark Fox Evans
Vincent L. Capuano
Elizabeth J. Haanes
Michael D. Specht
Kevin W. McCabe
Glenn J. Perry
Edward W. Yee
Grant E. Reed
Virgil Lee Beaton
Theodore A. Wood
Joseph S. Ostroff
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson

Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
Young Tang
Christopher J. Walsh
W. Blake Coblenz
James J. Pohl
John T. Haran
Mark W. Rygiel

Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Ulrike Winkler
Bryan L. Skelton*
Paul A. Calvo
Robert A. Schwartzman
C. Matthew Rozier
Alexandra K. Pechhold

Registered Patent Agents*
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Julie A. Heider
Mita Mukherjee

Scott M. Woodhouse
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer
Aaron S. Lukas
Gaurav Asthana

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie
Christopher P. Wrist

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

April 18, 2007

WRITER'S DIRECT NUMBER:

(202) 772-8591

INTERNET ADDRESS:

JMILLS@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1642

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Appl. No. 10/765,568; Filed: January 28, 2004
For: **Method for Evaluating the Efficacy of Certain Cancer Treatments**
Inventors: CHANG *et al.*
Our Ref: 2474.0100001/BJD/JKM

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement;
2. IDS Form PTO/SB/08A (1 page) citing 1 document (FP1);
3. IDS Form PTO/SB/08B (5 pages) citing 45 documents (NPL1-NPL45);
4. One (1) copy of Documents FPL1 and NPL1-NPL45; and
5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.


Jeffrey K. Mills
Agent for Applicants
Registration No. 56,413

JKM/TCS/lam
Enclosures

663000_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

CHANG *et al.*

Appl. No.: 10/765,568

Filed: January 28, 2004

For: **Method for Evaluating the
Efficacy of Certain Cancer
Treatments**

Confirmation No.: 8131

Art Unit: 1642

Examiner: HALVORSON, Mark

Atty. Docket: 2474.0100001/BJD/JKM

**First Supplemental Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. This First Supplemental Information Disclosure Statement is a continuation of the Applicants' Information Disclosure Statement filed on August 18, 2005, in connection with the above-captioned application.

Copies of documents **FP1** and **NPL1-NPL45** are submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Jeffrey K. Mills
Agent for Applicants
Registration No. 56,413

Date: April 18, 2002

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
661038v1



Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(Use as many sheets as necessary)


Application Number	10/765,568
Filing Date	January 28, 2004
First Named Inventor	CHANG, Esther H.
Art Unit	1642
Examiner Name	HALVORSON, M.
Attorney Docket Number	2474.0100001/BJD/JKM

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (07-06)

Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Privacy Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/765,568
				Filing Date	January 28, 2004
				First Named Inventor	CHANG, Esther H.
				Art Unit	1642
				Examiner Name	HALVORSON, M.
Sheet	1	of	5	Attorney Docket Number	2474.0100001/BJD/JKM

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	ABOUNADER, R., <i>et al.</i> , "In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis," <i>FASEB J.</i> 16:108-110, Federation of American Societies for Experimental Biology (January 2002)	
	NPL2	ALLEN, T.M., <i>et al.</i> , "A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells," <i>Biochim. Biophys. Acta</i> 1237:99-108, Elsevier Science Inc. (1995)	
	NPL3	ALLEN, T.M., <i>et al.</i> , "Antibody-Targeted Stealth Liposomes" in <i>Stealth Liposomes</i> , Lasic, D.D. and Martin, F.J., eds., CRC Press Inc., Boca Raton, FL, pp. 233-244 (1995)	
	NPL4	AOKI, K., <i>et al.</i> , "Liposome-mediated <i>in Vivo</i> Gene Transfer of Antisense K-ras Construct Inhibits Pancreatic Tumor Dissemination in the Murine Peritoneal Cavity," <i>Cancer Res.</i> 55:3810-3816, American Association for Cancer Research (1995)	
	NPL5	BANNERJI, R., <i>et al.</i> , "Campath-1H antibody induces transmembrane signaling <i>in vitro</i> and <i>in vivo</i> in patients with chronic lymphocytic leukemia (CLL) and promotes tumor clearance in part through caspase mediated apoptosis," <i>Blood</i> 98:808a, American Society of Hematology (2001)	
	NPL6	BYRD, J.C., <i>et al.</i> , "The mechanism of tumor cell clearance by rituximab <i>in vivo</i> in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction," <i>Blood</i> 99:1038-1043, American Society of Hematology (February 2002)	
	NPL7	CHENG, P.-W., "Receptor Ligand-Facilitated Gene Transfer: Enhancement of Liposome-Mediated Gene Transfer and Expression by Transferrin," <i>Human Gene Ther.</i> 7:275-282, Mary Ann Liebert, Inc. (1996)	
	NPL8	CRISTIANO, R.J. and CURIEL, D.T., "Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway," <i>Cancer Gene Ther.</i> 3:49-57, Nature Publishing Group (1996)	
	NPL9	CRYNS, V. and YUAN, J., "Proteases to die for," <i>Gene Dev.</i> 12:1551-1570, Cold Spring Harbor Laboratory Press (1998)	
	NPL10	ELLIOTT, R.L., <i>et al.</i> , "Breast Carcinoma and the Role of Iron Metabolism: A Cytochemical, Tissue Culture, and Ultrastructural Study," <i>Ann. N. Y. Acad. Sci.</i> 698:159-166, New York Academy of Sciences (1993)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/765,568
				Filing Date	January 28, 2004
				First Named Inventor	CHANG, Esther H.
				Art Unit	1642
				Examiner Name	HALVORSON, M.
Sheet	2	of	5	Attorney Docket Number	2474.0100001/BJD/JKM

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL11	ESTROV, Z., <i>et al.</i> , "Caspase 2 and Caspase 3 Protein Levels as Predictors of Survival in Acute Myelogenous Leukemia," <i>Blood</i> 92:3090-3097, American Society of Hematology (1998)	
	NPL12	EVAN, G.I. and VOUSDEN, K.H., "Proliferation, cell cycle and apoptosis in cancer," <i>Nature</i> 411:342-348, Nature Publishing Group (2001)	
	NPL13	FELGNER, P.L., <i>et al.</i> , "Improved Cationic Lipid Formulations for <i>In Vivo</i> Gene Therapy," <i>Ann. N. Y. Acad. Sci.</i> 772:126-139, New York Academy of Sciences (1995)	
	NPL14	FENNELL, D.A., <i>et al.</i> , "In vivo suppression of Bcl-X _L expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model," <i>Brit. J. Haematol.</i> 112:706-713, Blackwell Science Ltd. (2001)	
	NPL15	HANAHAN, D. and WEINBERG, R.A., "The Hallmarks of Cancer," <i>Cell</i> 100:57-70, Cell Press (2000)	
	NPL16	HAYAMI, S., <i>et al.</i> , "Increase of Caspase-3 Activity in Rat Liver and Plasma by Thioacetamide," <i>Biochem. Pharmacol.</i> 58:1941-1943, Elsevier Science Inc. (1999)	
	NPL17	HAYAMI, S., <i>et al.</i> , "Change in Caspase-3-Like Protease in the Liver and Plasma during Rat Liver Regeneration Following Partial Hepatectomy," <i>Biochem. Pharmacol.</i> 60:1883-1886, Elsevier Science Inc. (2000)	
	NPL18	HORVITZ, H.R., "Genetic Control of Programmed Cell Death in the Nematode <i>Caenorhabditis elegans</i> ," <i>Cancer Res.</i> 59:1701s-1706s, American Association for Cancer Research (1999)	
	NPL19	HUWYLER, J., <i>et al.</i> , "Brain drug delivery of small molecules using immunoliposomes," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 93:14164-14169, National Academy of Sciences (1996)	
	NPL20	JÄÄTTELÄ, M., "Escaping Cell Death: Survival Proteins in Cancer," <i>Exp. Cell Res.</i> 248:30-43, Academic Press (1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/765,568
				Filing Date	January 28, 2004
				First Named Inventor	CHANG, Esther H.
				Art Unit	1642
				Examiner Name	HALVORSON, M.
Sheet	3	of	5	Attorney Docket Number	2474.0100001/BJD/JKM

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL21	JACOBSON, M.D., <i>et al.</i> , "Programmed Cell Death in Animal Development," <i>Cell</i> 88:347-354, Cell Press (1997)	
	NPL22	JIANG, A., <i>et al.</i> , "Cell-Type-Specific Gene Transfer into Human Cells with Retroviral Vectors That Display Single-Chain Antibodies," <i>J. Virol.</i> 72:10148-10156, American Society For Microbiology (1998)	
	NPL23	KITADA, S., <i>et al.</i> , "The Mechanism of <i>In Vivo</i> Leukemia Cell Clearance by Rituximab in Patients with CLL Involves Apoptosis by a Caspase 9 Pathway," <i>Blood</i> 96:515a, Abstract No. 2216, American Society of Hematology (2000)	
	NPL24	KÖHLER, C., <i>et al.</i> , "Evaluation of caspase activity in apoptotic cells," <i>J. Immunol. Methods</i> 265:97-110, North-Holland Pub. Co. (July 2002)	
	NPL25	KONISHI, H., <i>et al.</i> , "Targeting Strategy for Gene Delivery to Carcinoembryonic Antigen-Producing Cancer Cells by Retrovirus Displaying a Single-Chain Variable Fragment Antibody," <i>Human Gene Ther.</i> 9:235-248, Mary Ann Liebert (1998)	
	NPL26	LEE, R.J. and HUANG, L., "Folate-targeted, Anionic Liposome-entrapped Polylysine-condensed DNA for Tumor Cell-specific Gene Transfer," <i>J. Biol. Chem.</i> 271:8481-8487, American Society for Biochemistry and Molecular Biology (1996)	
	NPL27	LEWIS, J.G., <i>et al.</i> , "A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 93:3176-3181, National Academy of Sciences (1996)	
	NPL28	MANCINI, M., <i>et al.</i> , "The Caspase-3 Precursor Has a Cytosolic and Mitochondrial Distribution: Implications for Apoptotic Signaling," <i>J. Cell Biol.</i> 140:1485-1495, Rockefeller University Press (1998)	
	NPL29	MARTIN, F., <i>et al.</i> , "Retroviral Vector Targeting to Melanoma Cells by Single-Chain Antibody Incorporation in Envelope," <i>Human Gene Ther.</i> 9:737-746, Mary Ann Liebert (1998)	
	NPL30	MASSING, U., "Cancer therapy with liposomal formulations of anticancer drugs," <i>Int. J. Clin. Pharmacol. Ther.</i> 35:87-90, Dustri-Verlag Dr. K. Feistle (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/765,568
				Filing Date	January 28, 2004
				First Named Inventor	CHANG, Esther H.
				Art Unit	1642
				Examiner Name	HALVORSON, M.
Sheet	4	of	5	Attorney Docket Number	2474.0100001/BJD/JKM

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL31	MATHIASSEN, I.S. and JÄÄTTELÄ, M., "Triggering caspase-independent cell death to combat cancer," <i>Trends Mol. Med.</i> 8:212-220, Elsevier Science Ltd. (April 2002)	
	NPL32	MIYAMOTO, T., <i>et al.</i> , "Transferrin receptor in oral tumors," <i>Int. J. Oral Maxillofac. Surg.</i> 23:430-433, Munksgaard (1994)	
	NPL33	NAWROCKI, S.T., <i>et al.</i> , "Effects of the Proteasome Inhibitor PS-341 on Apoptosis and Angiogenesis in Orthotopic Human Pancreatic Tumor Xenografts," <i>Molec. Cancer Ther.</i> 1:1243-1253, American Association for Cancer Research, Inc. (December 2002)	
	NPL34	NICHOLSON, D.W. and THORNBERRY, N.A., "Caspases: killer proteases," <i>Trends Biochem. Sci.</i> 22:299-306, Elsevier Science Ltd. (1997)	
	NPL35	NICHOLSON, I.C., <i>et al.</i> , "Construction and Characterisation of a Functional CD19 Specific Single Chain Fv Fragment for Immunotherapy of B Lineage Leukaemia and Lymphoma," <i>Mol. Immunol.</i> 34:1157-1165, Pergamon Press (1997)	
	NPL36	NUÑEZ, G., <i>et al.</i> , "Caspases: the proteases of the apoptotic pathway," <i>Oncogene</i> 17:3237-3245, Nature Publishing Group (1998)	
	NPL37	PARK, J.W., <i>et al.</i> , "Development of anti-p185 ^{HER2} immunoliposomes for cancer therapy," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 92:1327-1331, National Academy of Sciences (1995)	
	NPL38	POON, R.Y.M., "Advances in Monoclonal Antibody Applications: Bispecific Antibodies" in <i>Biotechnology International: International Developments in the Biotechnology Industry</i> , Fox, F. and Connor, T.H., eds., Universal Medical Press, Inc., San Francisco, CA, pp. 113-128 (1997)	
	NPL39	SUN, F., <i>et al.</i> , "Evaluation of oxidative stress based on lipid hydroperoxide, vitamin C and vitamin E during apoptosis and necrosis caused by thioacetamide in rat liver," <i>Biochim. Biophys. Acta</i> 1500:181-185, Elsevier Science B.V. (2000)	
	NPL40	SUN, F., <i>et al.</i> , "Evaluation of oxidative stress during apoptosis and necrosis caused by carbon tetrachloride in rat liver," <i>Biochim. Biophys. Acta</i> 1535:186-191, Elsevier Science B.V. (2001)	
Examiner Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/765,568
				Filing Date	January 28, 2004
				First Named Inventor	CHANG, Esther H.
				Art Unit	1642
				Examiner Name	HALVORSON, M.
Sheet	5	of	5	Attorney Docket Number	2474.0100001/BJD/JKM

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL41	SUN, F., <i>et al.</i> , "Evaluation of oxidation stress during apoptosis and necrosis caused by D-galactosamine in rat liver," <i>Biochem. Pharmacol.</i> 65:101-107, Elsevier Science Inc. (January 2003)	
	NPL42	SUZUKI, S., <i>et al.</i> , "Modulation of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an immunoliposome targeting transferring receptor," <i>Br. J. Cancer</i> 76:83-89, Nature Publishing Group (1997)	
	NPL43	THIERRY, A.R., <i>et al.</i> , "Systemic gene therapy: Biodistribution and long-term expression of a transgene in mice," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 92:9742-9746, National Academy of Science (1995)	
	NPL44	THORSTENSEN, K. and ROMSLO, I., "The Transferrin Receptor: Its Diagnostic Value and its Potential as Therapeutic Target," <i>Scand. J. Clin. Lab. Invest. Suppl.</i> 215:113-120, Universitetsforlaget (1993)	
	NPL45	WHITACRE, C.M., <i>et al.</i> , "Photodynamic Therapy with the Phthalocyanine Photosensitizer Pc 4 of SW480 Human Colon Cancer Xenografts in Athymic Mice," <i>Clin. Cancer. Res.</i> 6:2021-2027, American Association for Cancer Research (2000)	

587436v1

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.